Loading...
•
Dec 31, 2021
Taysha Gene Therapies Q4 2021 Earnings Report
Taysha Gene Therapies reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $50.4 million for the fourth quarter of 2021. The company is prioritizing key registration-directed programs in GAN and Rett syndrome and expects its cash runway to extend into Q4 2023.
Reported positive clinical efficacy and safety data for high dose cohort and long-term durability data across all therapeutic dose cohorts for TSHA-120 in GAN.
Clinical Trial Application (CTA) approved by Health Canada in March 2022.
Reported positive preliminary clinical safety data for first-generation construct in CLN7 Batten disease from UTSW-sponsored clinical trial.
Prioritizing key value-driving registration-directed programs, GAN and Rett syndrome.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates several milestones in 2022, including regulatory updates for TSHA-120 in GAN, first-in-human preliminary Phase 1/2 data for TSHA-102 in Rett syndrome, initiation of clinical development for TSHA-105 in SLC13A5 deficiency, continued clinical development for TSHA-118 in CLN1 disease, and continued clinical development of the first-generation construct for CLN7 disease.
Positive Outlook
- Regulatory update for TSHA-120 in GAN by mid-2022
- First-in-human preliminary Phase 1/2 data for TSHA-102 in Rett syndrome by year-end 2022
- Initiation of clinical development for TSHA-105 in SLC13A5 deficiency in 2022
- Continued clinical development for TSHA-118 in CLN1 disease in 2022
- Continued clinical development of the first-generation construct for CLN7 disease in 2022